Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Progress Over Perfection: Lessons From Garment Factories Fighting Heat Stress - 2Scientists find new clues to why female fertility declines with age
- 3Corcept Therapeutics shares surge as lead drug gets FDA nod for ovarian cancer
- 4The Solution to Defeating Tarrying: Systems for Expanded Efficiency
- 5Irish defence minister's trip to Lebanon cancelled
- Portable Installment Answers for Independent ventures
- Instructions to Upgrade the Proficiency of Your Sunlight powered chargers
- Vote in favor of your Favored kind of footwear
- French and Malaysian authorities are investigating Grok for generating sexualized deepfakes
- Man triggers smoke bomb during failed crypto robbery
- California officials warn against foraging wild mushrooms after deadly poisoning outbreak
- Misinterpretations and Mistakes Portrayed by Hollywood in the General set of laws
- Practice environmental safety in Style: Divulging Famous Electric Vehicle Brands
- 6 Top of the line Lodgings All over The Planet, Which One Do You Concur With
